Posted on 7702
January 2021, Thousand Oaks Biopharmaceuticals Group (“Thousand Oaks”) announced that it had signed a Joint Venture agreement with WSG Group in Busan, Korea, to establish a bioprocess solution joint venture (including cell culture media, single-use technology, and related technologies and products) in early 2021. The Joint Venture will speed up and boost development of the Korean Biopharmaceutical industry by supplying serum-free cell culture media at commercial scale. This cooperation also marks another milestone for JSBiosciences (a fully owned subsidiary of Thousand Oaks) the leading cell culture media supplier to enter the international market.
Thousand Oaks Biopharmaceuticals Inked a Joint Venture Agreement with Korea’s WSG Group (Graphic: Business Wire)